Echelon Biosciences Inc.
SEARCH






ASSAYS AND REAGENTS FOR DRUG DISCOVERY IN LIPID SIGNALING PATHWAYS
FORUMS
PRODUCT CATEGORIES
Antibodies and Lipid Recognition Proteins
Assay Service
Assays
Enzymes
Heme Pathway
Inhibitors
Inositol Phosphates
Intracellular Lipid Delivery Systems
Isoprenoids
Lipid-Protein Interaction Tools
Lipids
Lysophospholipid Products
MEP Pathway intermediates
Phosphoinositide Reagents and Derivatives
Phospholipase Substrates
Protein Kinases & Phosphatases
Sphingolipid Products
PURCHASE ASSISTANCE
Order Status
My Quotation
My Account
DISTRIBUTORS
TECHNICAL SUPPORT / FAQ
NEWS
TECHNICAL DATA SHEETS &     PROTOCOLS
PUBLICATIONS
BROWSE BY PATHWAY
FEEDBACK
SUBMIT PRODUCT IDEAS
Direct:801-588-0455
Fax:801-588-0497
 

About US

About Frontier Scientific     Employment Opportunities     Management     Scientific Background     conferences    

Echelon Biosciences was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, and was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. The company has since changed its name to Echelon Biosciences Incorporated. The company was organized to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.

From 1997 through 2004 Echelon primarily used government grants and product sales revenues to fund its research efforts. In early 2005 Echelon was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP antiinfectives, PI 3-Kinase small molecule program and catalog business.

In late 2007, Echelon was acquired by Frontier Scientific Inc. Frontier is based in Logan, Utah; specializing in Porphyrin and related compounds and Photo Dynamic Therapy. The new ownership allows expanded research and funding for many positive aspects for both Echelon and Frontier.